Study Comparing the Effect of Drug Abelacimab Relative to Dalteparin on Venous Thromboembolism (VTE) Recurrence and Bleeding in Patients with Gastrointestinal (GI) / Genitourinary (GU) Cancer Associated VTE
Brief description of study
This research study is being done to see if patients taking the study drug abelacimab have fewer bleeding events compared to those taking dalteparin.
Your participation will last for about 8 months (6 months of treatment and 2 months of follow up).
Participants may be paid up to a total of $1,000.00 (10 total visits).
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Venous Thromboembolism,VTE,gastrointestinal,genitourinary
-
Age: Between 18 Years - 99 Years
-
Gender: All
Updated on
09 Mar 2024.
Study ID: 851763
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
A copy of the message has been sent to your email
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting